Please check your internet connection and try again.
# Pantoprazole
## Overview
Pantoprazole is a proton pump inhibitor (PPI) that suppresses gastric acid secretion.
## Primary Indications
* Healing of erosive esophagitis associated with gastroesophageal reflux disease (GERD)
* Maintenance of healing of erosive esophagitis
* Treatment of pathological hypersecretory conditions, including Zollinger-Ellison syndrome
## Adult Dosing
* **Erosive esophagitis healing:** 40 mg orally once daily for up to 8 weeks.
* **Maintenance of healing:** 40 mg orally once daily.
* **Pathological hypersecretory conditions:** Starting dose is typically 40 mg orally twice daily, but may be increased as clinically indicated. Doses up to 240 mg daily have been administered intravenously.
## Pediatric Dosing
* **Erosive esophagitis healing (12 to 17 years):** 40 mg orally once daily for up to 4 weeks.
* **Erosive esophagitis healing (5 to 11 years):** 20 mg orally once daily for up to 4 weeks. Consider 40 mg daily for more severe esophagitis.
* **GERD (5 to 11 years):** 20 mg orally once daily for up to 8 weeks.
## Dose Adjustments
No dose adjustment is typically required for renal or hepatic impairment, although caution is advised in severe hepatic impairment.
## Contraindications
Hypersensitivity to pantoprazole or any component of the formulation.
## Adverse Effects
Common adverse effects include headache, diarrhea, nausea, abdominal pain, and dizziness. Long-term use may be associated with vitamin B12 deficiency, hypomagnesemia, and an increased risk of Clostridium difficile-associated diarrhea, bone fractures, and possibly certain infections.
## Key Drug Interactions
* **Drugs requiring gastric acid for absorption:** Ketoconazole, itraconazole, posaconazole, iron salts, and vitamin B12 absorption may be decreased.
* **Methotrexate:** Pantoprazole may increase methotrexate levels.
* **CYP2C19 substrates:** While generally considered less of an inducer/inhibitor than some other PPIs, caution may be warranted with drugs primarily metabolized by CYP2C19 if concurrent use is necessary.
## Monitoring
* Monitor for signs and symptoms of hypomagnesemia (e.g., tremor, tetany, seizures).
* Monitor for signs and symptoms of Clostridium difficile infection.
* Consider monitoring vitamin B12 levels in patients on long-term therapy.
* Consider bone mineral density assessment in patients at risk for osteoporosis.
## Clinical Pearls
* Administer orally before a meal.
* For delayed-release tablets, do not crush or chew.
* Intravenous formulation is available for patients unable to take oral medication.
* Duration of therapy should be the shortest necessary to treat the condition.
***
This information is intended for healthcare professionals. Please consult the official prescribing information and relevant literature for complete details. Always verify current prescribing information with the manufacturer's most recent approved labeling.
